Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity1
暂无分享,去创建一个
C. Yeh | Hui-min Peng | Tse-Ching Chen | A. Dutta | Ching-Tai Huang | Chun-Yen Lin | Yung-Chang Lin | Li-Yuan Chang
[1] Howard,et al. Collected studies on immunity , 2009 .
[2] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[3] Qizhi Tang,et al. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation , 2008, Nature Immunology.
[4] F. Marincola,et al. Tumour immunity: effector response to tumour and role of the microenvironment , 2008, The Lancet.
[5] T. Yi,et al. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. , 2007, Blood.
[6] T. Ley,et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. , 2007, Immunity.
[7] I. Sheen,et al. Liver injury is associated with enhanced regulatory T‐cell activity in patients with chronic hepatitis B , 2007, Journal of viral hepatitis.
[8] A. Rudensky,et al. Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory disease , 2007, The Journal of experimental medicine.
[9] E. Shevach,et al. Distinct Subsets of FoxP3 Regulatory T Cells Participate in the Control of Immune Responses , 2007 .
[10] T. Curiel,et al. Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.
[11] S. Hirohashi,et al. FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis , 2007, Clinical Cancer Research.
[12] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Y. Belkaid,et al. CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence , 2006, The Journal of experimental medicine.
[14] A. Frey,et al. Effector‐phase tolerance: another mechanism of how cancer escapes antitumor immune response , 2006, Journal of leukocyte biology.
[15] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[16] F. Powrie,et al. Essential role for CD103 in the T cell–mediated regulation of experimental colitis , 2005, The Journal of experimental medicine.
[17] Manuela Gariboldi,et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[18] L. Old,et al. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.
[19] Y. Belkaid,et al. A Role for CD103 in the Retention of CD4+CD25+ Treg and Control of Leishmania major Infection1 , 2005, The Journal of Immunology.
[20] M. Dorf,et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor , 2005, The Journal of experimental medicine.
[21] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[22] Youjin Lee,et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors , 2005, The Journal of experimental medicine.
[23] R. Weissleder,et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .
[24] A. Houghton,et al. Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.
[25] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[26] J. Buer,et al. Developmental Stage, Phenotype, and Migration Distinguish Naive- and Effector/Memory-like CD4+ Regulatory T Cells , 2004, The Journal of experimental medicine.
[27] Y. Belkaid,et al. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity , 2002, Nature.
[28] T. Eberlein,et al. Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.
[29] Ethan M. Shevach,et al. CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.
[30] Hiroshi Tanaka,et al. Depletion of CD4+CD25+ Regulatory Cells Augments the Generation of Specific Immune T Cells in Tumor-Draining Lymph Nodes , 2002, Journal of immunotherapy.
[31] T. Tüting,et al. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. , 2001, Cancer research.
[32] A. Frey,et al. CD8+ Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic Activity Due to Defective Microtubule-Organizing Center Mobilization and Lytic Granule Exocytosis , 2001, The Journal of Immunology.
[33] D. Pardoll. Stress, NK Receptors, and Immune Surveillance , 2001, Science.
[34] T. Schumacher,et al. Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.
[35] R. Offringa,et al. Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine , 2001, The Journal of experimental medicine.
[36] A. Frey,et al. CD8+ Tumor-Infiltrating Lymphocytes Are Primed for Fas-Mediated Activation-Induced Cell Death But Are Not Apoptotic In Situ1 , 2001, The Journal of Immunology.
[37] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[38] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[39] E. Jaffee,et al. Cancer Vaccines , 1997, Current protocols in human genetics.
[40] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[41] R. North,et al. T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity [published erratum appears in J Exp Med 1986 Dec 1;164(6):2131] , 1986, The Journal of experimental medicine.
[42] S. Rosenberg,et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.
[43] I. Bursuker,et al. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells , 1984, The Journal of experimental medicine.
[44] R. North,et al. The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity , 1978, The Journal of experimental medicine.
[45] S. Howell,et al. Defects in cell‐mediated immunity during growth of a syngeneic simian virus‐induced tumor , 1975, International journal of cancer.
[46] P. Deckers,et al. The adoptive transfer of concomitant immunity to murine tumor isografts with spleen cells from tumor-bearing animals. , 1971, Cancer research.
[47] E. F. Bashford. FOURTH SCIENTIFIC REPORT OF THE INVESTIGATIONS OF THE IMPERIAL CANCER RESEARCH FUND , 1912 .
[48] A. Moreira,et al. Systemic and Local Characterization of Regulatory T Cells in a Chronic Fungal Infection in Humans , 2006 .
[49] J. Serody,et al. Cells during Acute Graft-versus-host Disease Regulatory T + Cd25 + Critical Role for Ccr5 in the Function of Donor Cd4 , 2005 .
[50] C. Griscelli,et al. A monoclonal antibody (HML‐1) defining a novel membrane molecule present on human intestinal lymphocytes , 1987, European journal of immunology.